Literature DB >> 21911734

Association of Alzheimer disease pathology with abnormal lipid metabolism: the Hisayama Study.

T Matsuzaki1, K Sasaki, J Hata, Y Hirakawa, K Fujimi, T Ninomiya, S O Suzuki, S Kanba, Y Kiyohara, T Iwaki.   

Abstract

OBJECTIVE: The relationship between lipid profiles and Alzheimer disease (AD) pathology at the population level is unclear. We searched for evidence of AD-related pathologic risk of abnormal lipid metabolism.
METHODS: This study included brain specimens from a series of 147 autopsies performed between 1998 and 2003 of residents in Hisayama town, Japan (76 men and 71 women), who underwent clinical examinations in 1988. Lipid profiles, such as total cholesterol (TC), triglycerides, and high-density lipoprotein cholesterol (HDLC), were measured in 1988. Low-density lipoprotein cholesterol (LDLC) was calculated using the Friedewald formula. Neuritic plaques (NPs) were assessed according to the Consortium to Establish a Registry for Alzheimer's Disease guidelines (CERAD) and neurofibrillary tangles (NFTs) were assessed according to Braak stage. Associations between each lipid profile and AD pathology were examined by analysis of covariance and logistic regression analyses.
RESULTS: Adjusted means of TC, LDLC, TC/HDLC, LDLC/HDLC, and non-HDLC (defined as TC-HDLC) were significantly higher in subjects with NPs, even in sparse to moderate stages (CERAD = 1 or 2), compared to subjects without NPs in multivariate models including APOE ε4 carrier and other confounding factors. The subjects in the highest quartiles of these lipid profiles had significantly higher risks of NPs compared to subjects in the lower respective quartiles, which may suggest a threshold effect. Conversely, there was no relationship between any lipid profile and NFTs.
CONCLUSION: The results of this study suggest that dyslipidemia increases the risk of plaque-type pathology.

Entities:  

Mesh:

Year:  2011        PMID: 21911734     DOI: 10.1212/WNL.0b013e31822e145d

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  35 in total

1.  Dysregulated bile acid synthesis and dysbiosis are implicated in Western diet-induced systemic inflammation, microglial activation, and reduced neuroplasticity.

Authors:  Prasant Kumar Jena; Lili Sheng; Jacopo Di Lucente; Lee-Way Jin; Izumi Maezawa; Yu-Jui Yvonne Wan
Journal:  FASEB J       Date:  2018-01-10       Impact factor: 5.191

2.  Association between Cholesterol Exposure and Neuropathological Findings: The ACT Study.

Authors:  Brianne M Bettcher; M Colin Ard; Bruce R Reed; Andreana Benitez; Amanda Simmons; Eric B Larson; Josh A Sonnen; Thomas J Montine; Ge Li; C Dirk Keene; Paul K Crane; Dan Mungas
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

3.  Disease risk factors identified through shared genetic architecture and electronic medical records.

Authors:  Li Li; David J Ruau; Chirag J Patel; Susan C Weber; Rong Chen; Nicholas P Tatonetti; Joel T Dudley; Atul J Butte
Journal:  Sci Transl Med       Date:  2014-04-30       Impact factor: 17.956

4.  Impaired glycemia increases disease progression in mild cognitive impairment.

Authors:  Jill K Morris; Eric D Vidoni; Robyn A Honea; Jeffrey M Burns
Journal:  Neurobiol Aging       Date:  2013-10-23       Impact factor: 4.673

5.  Association of Hypercholesterolemia with Alzheimer's Disease Pathology and Cerebral Amyloid Angiopathy.

Authors:  Chenjia Xu; Liana G Apostolova; Adrian L Oblak; Sujuan Gao
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

6.  Role of endolysosomes and cholesterol in the pathogenesis of Alzheimer's disease: Insights into why statins might not provide clinical benefit.

Authors:  Xuesong Chen; Liang Hui; Jonathan D Geiger
Journal:  Austin J Pharmacol Ther       Date:  2014-08-26

Review 7.  Cholesterol, statins, and dementia: what the cardiologist should know.

Authors:  Brett L Wanamaker; Kristopher J Swiger; Roger S Blumenthal; Seth S Martin
Journal:  Clin Cardiol       Date:  2015-04-13       Impact factor: 2.882

8.  Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease.

Authors:  Andrew J Schork; Yunpeng Wang; Rahul S Desikan; Wesley K Thompson; Abbas Dehghan; Paul M Ridker; Daniel I Chasman; Linda K McEvoy; Dominic Holland; Chi-Hua Chen; David S Karow; James B Brewer; Christopher P Hess; Julie Williams; Rebecca Sims; Michael C O'Donovan; Seung Hoan Choi; Joshua C Bis; M Arfan Ikram; Vilmundur Gudnason; Anita L DeStefano; Sven J van der Lee; Bruce M Psaty; Cornelia M van Duijn; Lenore Launer; Sudha Seshadri; Margaret A Pericak-Vance; Richard Mayeux; Jonathan L Haines; Lindsay A Farrer; John Hardy; Ingun Dina Ulstein; Dag Aarsland; Tormod Fladby; Linda R White; Sigrid B Sando; Arvid Rongve; Aree Witoelar; Srdjan Djurovic; Bradley T Hyman; Jon Snaedal; Stacy Steinberg; Hreinn Stefansson; Kari Stefansson; Gerard D Schellenberg; Ole A Andreassen; Anders M Dale
Journal:  Circulation       Date:  2015-04-10       Impact factor: 29.690

Review 9.  Role of cholesterol in APP metabolism and its significance in Alzheimer's disease pathogenesis.

Authors:  M Maulik; D Westaway; J H Jhamandas; S Kar
Journal:  Mol Neurobiol       Date:  2012-09-16       Impact factor: 5.590

10.  Development of AD-Like Pathology in Skeletal Muscle.

Authors:  X Chen; N M Miller; Z Afghah; J D Geiger
Journal:  J Parkinsons Dis Alzheimers Dis       Date:  2019-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.